登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由南昌大学第二附属医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06554613,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed EGFR mutation-negative non-small cell lung cancer.
入选标准第 6 条
Staged as Stage IV according to the TNM system.
入选标准第 5 条
Has not received systemic antitumor treatment, and is intended to receive monotherapy or combined chemotherapy with a PD-1/PD-L1 inhibitor as first-line treatment.
入选标准第 7 条
Within 4 weeks prior to the first administration of the study drug, the subject had undergone major surgery;
排除标准第 5 条
Within 7 days prior to the first administration of the study drug, used strong inhibitors or inducers of CYP3A4.
排除标准第 6 条
ECOG score: 0-2 points.
入选标准第 3 条
Normal major organ function, that is, meeting the following criteria: (1) Hematological examination criteria must be met: Hb≥90 g/L; ANC≥1.5×10\^9/L; PLT≥80×10\^9/L. (2) Biochemical examination must meet the following criteria: TBIL<1.5×ULN; ALT and AST<2.5×ULN; serum Cr≤1.25×ULN or endogenous creatinine clearance > 45 ml/min (Cockcroft-Gault formula).
入选标准第 8 条
Absolute neutrophil count <1.5×10\^9/L;
排除标准第 19 条
Platelet count <100×10\^9/L;
排除标准第 20 条
Hemoglobin <90 g/L (<9 g/dL);
排除标准第 21 条
If there is no definite liver metastasis, alanine aminotransferase > 3 times the upper limit of normal (ULN); if there is liver metastasis, alanine aminotransferase > 5×ULN;
排除标准第 22 条
If there is no definite liver metastasis, aspartate aminotransferase >3×ULN; if there is liver metastasis, aspartate aminotransferase > 5×ULN;
排除标准第 23 条
If there is no definite liver metastasis, total bilirubin > 1.5×ULN; or with Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastasis, total bilirubin > 3×ULN;
排除标准第 24 条
Creatinine > 1.5×ULN and creatinine clearance <50 mL/min (calculated by the Cockcroft-Gault formula); creatinine clearance is only required if creatinine > 1.5×ULN;
排除标准第 25 条
Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
排除标准第 28 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06554613,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Participants voluntarily enroll in this study and sign an informed consent form, with good compliance and cooperation with follow-up. Age is over 18 years old (including 18 years old) and under 75 years old (including 75 years old). ECOG score: 0-2 points. Expected survival is no less than 3 months. Staged as Stage IV according to the TNM system. Histologically or cytologically confirmed EGFR mutation-negative non-small cell lung cancer. Has not received systemic antitumor treatment, and is intended to receive monotherapy or combined chemotherapy with a PD-1/PD-L1 inhibitor as first-line treatment. Normal major organ function, that is, meeting the following criteria: (1) Hematological examination criteria must be met: Hb≥90 g/L; ANC≥1.5×10\^9/L; PLT≥80×10\^9/L. (2) Biochemical examination must meet the following criteria: TBIL<1.5×ULN; ALT and AST<2.5×ULN; serum Cr≤1.25×ULN or endogenous creatinine clearance > 45 ml/min (Cockcroft-Gault formula). Women of childbearing age must have taken reliable contraceptive measures and have undergone a pregnancy test (serum or urine) within 7 days before enrollment, with a negative result, and are willing to use appropriate methods of contraception during the trial period and for 8 weeks after the last administration of the trial medication. For men, they must agree to use appropriate methods of contraception during the trial period and for 8 weeks after the last administration of the trial medication or have undergone surgical sterilization.排除标准:Exclusion Criteria:
Have received any of the following treatments: Previously used any EGFR tyrosine kinase inhibitors; Previously received any chemotherapy for lung cancer; Previously received any radiotherapy for lung cancer (except palliative radiotherapy for bone metastases); Within 4 weeks prior to the first administration of the study drug, the subject had undergone major surgery; Within 7 days prior to the first administration of the study drug, used strong inhibitors or inducers of CYP3A4. Subjects with concurrent other malignant tumors, except for basal cell carcinoma of the skin and in situ cancer. Subjects with uncontrollable malignant pleural effusion and pericardial effusion. Subjects allergic to contrast agents for CT and MRI or any subjects who cannot tolerate MRI examination. As judged by the investigator, any serious or poorly controlled systemic diseases, such as uncontrolled hypertension, active bleeding diathesis, or active infection. Clinically severe gastrointestinal functional abnormalities that may affect the intake, transport, or absorption of the drug, such as the inability to take oral medication, uncontrollable nausea or vomiting, history of extensive gastrointestinal resection, unresolved recurrent diarrhea, atrophic gastritis, gastric diseases requiring long-term use of proton pump inhibitors, Crohn's disease, ulcerative colitis, etc. Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis. Meet any of the following cardiac examination results: The average of the corrected QT interval (QTcF) obtained from three ECG examinations at rest is > 470 msec; Resting ECG suggests conduction or ECG morphological abnormalities (such as complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block, and PR interval > 250 msec, etc.); There are any factors that increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concurrent medication of unexplained sudden death in direct relatives under the age of 40 or prolonged QT interval; Left ventricular ejection fraction (LVEF) < 50%. Insufficient bone marrow reserve or organ function, reaching any of the following laboratory limits: Absolute neutrophil count <1.5×10\^9/L; Platelet count <100×10\^9/L; Hemoglobin <90 g/L (<9 g/dL); If there is no definite liver metastasis, alanine aminotransferase > 3 times the upper limit of normal (ULN); if there is liver metastasis, alanine aminotransferase > 5×ULN; If there is no definite liver metastasis, aspartate aminotransferase >3×ULN; if there is liver metastasis, aspartate aminotransferase > 5×ULN; If there is no definite liver metastasis, total bilirubin > 1.5×ULN; or with Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastasis, total bilirubin > 3×ULN; Creatinine > 1.5×ULN and creatinine clearance <50 mL/min (calculated by the Cockcroft-Gault formula); creatinine clearance is only required if creatinine > 1.5×ULN; Serum albumin (ALB) <28 g/L. Active fungal, bacterial, and/or viral infections requiring systemic treatment. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period. History of interstitial lung disease, drug-induced interstitial lung disease, history of radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease. Subjects who, in the judgment of the investigator, may have poor compliance with the procedures and requirements of the study, such as subjects with a clear history of neurological or mental disorders, currently suffering from mental disorders, etc. Subjects whom the investigator judges to have any condition that endangers the safety of the subject or interferes with the evaluation of the study.
引自 ClinicalTrials.gov, NCT06554613, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06554613,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。